Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy

NCT03823989 is registered in ClinicalTrials.gov with Lipomedix Pharmaceuticals Inc. as lead sponsor.

NCT NCT03823989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03823989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b Study of Intravenously Administered Pegylated Liposomal Mitomycin C Lipid-based Prodrug (PROMITIL) in Combination With External Beam Radiotherapy in Patients With Advanced Cancer Requiring Palliative Radiotherapy
Lead sponsor
Lipomedix Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 3, 2019
Completion date
December 30, 2021
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic disease, solid tumor